Mucormycosis – review of literature and case report
Authors:
M. Čerňan 1; T. Szotkowski 1; R. Machová 1; M. Palová 1; P. Hamal 2; E. Faber 1
Authors‘ workplace:
Hemato-onkologická klinika LF UP a FN Olomouc
1; Ústav mikrobio logie LF UP a FN Olomouc
2
Published in:
Transfuze Hematol. dnes,27, 2021, No. 2, p. 137-145.
Category:
Review/Educational Papers
doi:
https://doi.org/10.48095/cctahd2021137
Overview
Mucormycosis represents a heterogenous group of rare invasive fungal infections associated with an aggressive course and high mortality. In Europe, patients undergoing intensive treatment for haematological malignancies and allogeneic hematopoietic stem cell transplantation are at the highest risk of mucormycosis infection. The lungs are the most frequently affected site in these patients. This work summarizes current data regarding epidemiology, diagnosis and treatment recommendations. The review article is followed by a case report regarding the rare manifestation of cutaneous mucormycosis in an acute myeloid leukaemia patient. The aim of this work is to provide current information regarding this group of opportunistic infections with an increasing clinical impact. Only early diagnosis and rapid initiation of complex therapy can lead to a favourable outcome and complete cure.
Keywords:
invasive fungal infection – mucormycosis – acute myeloid leukaemia – antimycotics
Sources
1. Pagano L, Busca A, Candoni A, et al. Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations. Blood Rev. 2017;31(2):17–29.
2. Binder U, Maurer E, Lass-Flörl C. Mucormycosis – from pathogen to the disease. Clin Microbiol Infect. 2014;Suppl 6:60–66.
3. Prakash H, Chakrabarti A. Global epidemiology of mucormycosis. J Fungi (Basel). 2019;5(1):26.
4. Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41(5):634–653.
5. Skiada A, Pagano L, Groll A, et al. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect. 2011;17(12):1859–1867.
6. Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis. 2005;191(8):1350–1360.
7. Petrikkos D, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis. 2012;54:23–34.
8. Skiada A, Lass-Floerl C, Klimko N, Ibrahim A, Roilides E, Petrikkos G. Challenges in the diagnosis and treatment of mucormycosis. Med Mycol. 2018;56(suppl 1):93–101.
9. Chakrabarti A. Mucormycosis in Asia. In: Chakrabarti A. (eds) Clinical practice of medical mycology in Asia. Singapore, Springer, 2017, 279–292.
10. Chakrabarti A, Chatterjee SS, Das A, et al. Invasive zygomycosis in India: experience in a tertiary care hospital. Postgrad Med J. 2009;85(1009):573–581.
11. Bitar D, Cauteren DV, Lanternier F, et al. Increasing incidence of zygomycosis (mucormycosis), France, 1997–2006. Emerg Infect Dis. 2009;15(9):1395–1401.
12. Torres-Narbona M, Guinea J, Martines-Alarcón J, Muñoz P, Gadea I, Bouza E. Impact of zygomycosis on microbiology workload: a survey study in Spain. J Clin Microbiol. 2007;45(6):2051–2053.
13. Lanternier F, Dannaoui E, Morizot G, et al. A global analysis of mucormycosis in France: The RetroZygo Study (2005–2007). Clin Infect Dis 2012;54(Suppl 1):35–43.
14. Rüping MJ, Heinz WJ, Kindo AJ, et al. Forty-one recent cases of invasive zygomycosis from a global clinical registry. J Antimicrob Chemother. 2010;65(2):296–302.
15. Pana ZD, Seidel D, Skiada A, et al. Invasive mucormycosis in children: an epidemiologic study in European and non-European countries based on two registries. BMC Infect Dis. 2016;16(1):667.
16. Lewis RE, Cahyame-Zuniga L, Leventakos K, et al. Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies: a 20-year autopsy study. Mycoses. 2013;56(6):638–645.
17. Charlier C, Hart E, Lefort A, et al. Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? J Antimicrob Chemother. 2006;57(3):384–410.
18. Weinbergerová B, Kabut T, Kocmanová I, et al. Změny v epidemiologii invazivních mykotických infekcí v českých a slovenských hematoonkologických centrech v letech 2005–2017: analýza dat FIND. Transfuze Hematol Dnes. 2019;25(2):186–196.
19. Sun HY, Singh N. Mucormycosis: its contemporary face and management strategies. Lancet Infect Dis. 2011;11(4):301–311.
20. Jeong W, Keighley C, Wolfe R, et al. The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. Clin Microbiol Infect. 2019;25(1):26–34.
21. Teixeira CA, Bettencourt Medeiros P, Leushner P, Almeida F. Rhinocerebral mucormycosis: literature review apropos of a rare entity. BMJ Case Rep. 2013;2013:bcr2012008552.
22. Lin E, Moua T, Limper AH. Pulmonary mucormycosis: clinical features and outcomes. Infection. 2017;45(4):443–448.
23. Lee FYW, Mossad SB, Adal KA. Pulmonary mucormycosis: the last 30 years. Arch Intern Med. 1999;159(12):1301–1309.
24. Feng J, Sun X. Characteristics of pulmonary mucormycosis and predictive risk factors for the outcome. Infection. 2018;46(4):503–512.
25. Chamilos G, Marom EM, Lewis RE, Lionakis MS, Kontoyiannis DP. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis. 2005;41(1):60–66.
26. Klimko N, Khostelidi S, Shadrivova O, et al. Contrasts between mucormycosis and aspergillosis in oncohematological patients. Medical Mycology. 2019;57(Suppl 2):138–144.
27. Skiada A, Petrikkos G. Cutaneous mucormycosis. Skinmed. 2013;11(3):155–159.
28. Chawla R, Sehgal S, Kumar S R, Mishra B. A rare case of mucormycosis of median sternotomy wound caused by Rhizopus arrhizus. Indian J Med Microbiol. 2007;25:419–421.
29. Spellberg B. Gastrointestinal mucormycosis. Gastroenterol Hepatol (N Y). 2012;8(2):140–142.
30. Morton J, Nguyen V, Ali T. Mucormycosis of the intestine. A rare complication in Crohn‘s disease. Gastroenterol Hepatol (N Y). 2012;8(2):137–140.
31. Tedder M, Spratt JA, Anstadt MP, Hegde SS, Tedder SD, Lowe JE. Pulmonary mucormycosis: results of medical and surgical therapy. Ann Thorac Surg. 1994;57(4):1044–1050.
32. Hammond SP, Baden LR, Marty FM. Mortality in hematologic malignancy and hematopoietic stem cell transplant patients with mucormycosis, 2001 to 2009. Antimicrob Agents Chemother. 2011;55(11):5018–5021.
33. Knox KS, Meinke L. Role of bronchoalveolar lavage diagnostics in fungal infections. Clin Chest Med. 2009;30(2):355–365.
34. Cornely OA, Arikan-Akdagli S, Dannaoui E, et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect. 2014;Suppl 3:5–26.
35. Skiada A, Lanternier F, Groll AH, et al. Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). Haematologica. 2013;98(4):492–504.
36. Millon L, Herbrecht R, F Grenouillet, et al. Early diagnosis and monitoring of mucormycosis by detection of circulating DNA in serum: retrospective analysis of 44 cases collected through the French Surveillance Network of Invasive Fungal Infections (RESSIF). Clin Microbiol Infect. 2016;22(9);810.e1–810.e8.
37. Mercier T, Reynders M, Beuselinck K, et al. Serial detection of circulating mucorales DNA in invasive mucormycosis: a retrospective multicenter evaluation. J Fungi (Basel). 2019;5(4):113.
38. Godoy MC, Viswanathan C, Marchiori E, et al. The reversed halo sign: update and differential diagnosis. Br J Radiol. 2012;85(1017):1226–1235.
39. Tissot F, Agrawal S, Pagano L, et al. ECIL-6 Guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica. 2017;102(3):433–444.
40. van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis. 2006;42(7):e61–e65.
41. Marty FM, Ostrosky-Zeichner L, Cornely A, et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis. 2016;16(7):828–837.
42. SÚKL: Cresemba 100mg cps. Souhrn údajů o přípravku. [online]. 2020 [cit. 2020-03-03]. Dostupné z: https:/ / www.sukl.cz/ .
43. Pagano L, Cornely OA, Busca A, et al. Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries. Haematologica. 2013;98(10):e127–e130.
44. Reed C, Bryant R, Ibrahim AS, et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis. 2008;47(3):364–371.
45. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356(4):335–347.
46. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356(4):348–359.
47. Lekakis LJ, Lawson A, Prante J, et al. Fatal rhizopus pneumonia in allogeneic stem cell transplant patients despite posaconazole prophylaxis: two cases and review of the literature. Biol Blood Marrow Transplant. 2009;15(8):991–995.
48. Oh J, Kang CI, Kim SH, et al. Antifungal prophylaxis with posaconazole tablet and oral suspension in patients with haematologic malignancy: Therapeutic drug monitoring, efficacy and risk factors for the suboptimal level. Mycoses. 2020;63(1):89–94.
49. SÚKL: Noxafil 40mg/ ml perorální suspenze. Souhrn údajů o přípravku. [online]. 2020 [cit. 2020-03-03]. Dostupné z: https:/ / www.sukl.cz/ .
50. Christiaens G, Hayette MP, Jacquemin D, Melin P, Mutsers J, De Mol P. An outbreak of Absidia corymbifera infection associated with bandage contamination in a burns unit. J Hosp Infect. 2005;61(1):88.
51. Chrenková V, Hubáček P, Weinbergerová B, et al. Invazivní mukormykóza u dětských hematoonkologických pacientů: zkušenosti 2005-2010. Klin Mikrobiol Infek Lek. 2012;18(4): 102–108.
52. Státní ústav pro kontrolu léčiv. [online]. 2020 [cit. 2020-03-03]. Dostupné z: https:/ / www.sukl.cz/ .
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2021 Issue 2
Most read in this issue
- Transfusion related acute lung injury (TRALI) prevention – selection of donors for producing plasma designated for clinical use
- A peripherally inserted central catheter is a safe means of ensuring long-term central venous access in patients with acute leukaemia – a single centre experience
- Mucormycosis – review of literature and case report
- Changes in the immune system of untreated patients with chronic lymphocytic leukaemia – part 1: adaptive immunity